OCUFEN
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Dec 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OCUFEN is an ophthalmic solution approved in 1986 for use in eye care, delivered as topical drops. The specific mechanism of action and indications are not documented in available data, limiting clinical positioning detail. As a small-molecule ophthalmic agent, it likely addresses inflammatory or refractive conditions common to eye care.
LOE Approaching
Approaching loss of exclusivity signals a transitional phase requiring defensive strategy; team focus likely shifting from growth to retention and generic preparation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OCUFEN offers limited career growth opportunity as a LOE-approaching product with zero linked job postings. This role suits professionals seeking stability in mature market management or defensive marketing strategy execution rather than product innovation.
Brand ManagerField Sales
Worked on OCUFEN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.